Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from CFA

BBLG: Bone Biologics Inks Important Supply Agreement

By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT

Benzinga

BLRX: 2021 Results

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT

Benzinga

RVPH: 2021 Results

By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

TLSA: KOL Discussion and SPMS 6-Month Results

By John Vandermosten, CFA NASDAQ:TLSA Introduction

Benzinga

ACHV: 2021 Results: ORCA-3 Underway, ORCA-V1 Soon to Start

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT

Benzinga

LGVN: Longeveron Continues to Make Progress

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT

Benzinga

CANG: December Quarter Results Met Expectations, but Soft Revenue Guidance for March Quarter Should Mark a Quarterly Trough for 2022

By T. Moore, CFA NYSE:CANG READ THE FULL CANG RESEARCH REPORT

Benzinga

Read news from The Economist, FT, and more,
with one subscription

LPCN: 2021 Results

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT

Benzinga

WKSP: Worksport updates investors and stakeholders with multiple press releases

By Thomas Kerr, CFA NASDAQ:WKSP READ THE FULL WKSP RESEARCH REPORT

Benzinga

DRIO: Future Brightens with $40M Raise & Sanofi Deal

By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT

Benzinga

NOVN: A Banner Year for Novan - 2021 Results

By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT

Benzinga

COCP: Cocrystal Pharma has secured funding to enter three clinical trials and fund planned operations through 2023

By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT

Benzinga

BBLG: Back Pain Solution Potentially on the Way

By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT

Benzinga

DYAI: Don't Put All Your Eggs in One Basket

By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

ALVOF: Alvopetro Energy's Organic Growth Plan Continues to be Successfully Executed. Production continues to grow and contract pricing significantly increased effective February 1st.

By Steven Ralston, CFA OTC:ALVOF | TSX:ALV.V READ THE FULL ALVOF RESEARCH REPORT

Benzinga

UHAL: AMERCO reports another strong quarter with revenues above expectations. Adjusted for seasonality of the company's businesses, UHAL continues to experience robust demand and strong pricing in the current environment.

By Steven Ralston, CFA NASDAQ:UHAL READ THE FULL UHAL RESEARCH REPORT

Benzinga

BTCY: Initiating Coverage – Outpatient Remote Cardiac Health Monitoring & Ecosystem with Emerging Growth Company Profile

By T. Moore, CFA NASDAQ:BTCY READ THE FULL BTCY RESEARCH REPORT

Benzinga

UCASU: Diversification into agriculture properties continues

By Beth Senko, CFA OTC:UCASU READ THE FULL UCASU RESEARCH REPORT

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

SQZ: IND Cleared for Enhanced APCs

By John Vandermosten, CFA NYSE:SQZ READ THE FULL SQZ RESEARCH REPORT

Benzinga

ACHV: The Final Phase III Begins

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT

Benzinga

Why The Stock Market Is 'Not Out Of The Woods Yet'

Cameron Dawson, CFA and chief market strategist at Fieldpoint Private, joined Benzinga’s PreMarket Prep show Tuesday morning.

Benzinga

BIOAF: Third Quarter Results

By John Vandermosten, CFA OTC:BIOAF READ THE FULL BIOAF RESEARCH REPORT

Benzinga

BLRX: Initiating on BioLineRx: Mobilizing the Troops with Motixafortide

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT

Benzinga

LGVN: Using Cellular Technology to Ease Major Medical Issues

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT

Benzinga

DRIO: 2022 Outlook, Physimax Acquisition

By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.